The global Live Attenuated Varicella Vaccine market was valued at US$ 4174 million in 2023 and is anticipated to reach US$ 5693.2 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.

Live Attenuated Varicella Vaccine Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Varicella Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Varicella Vaccine.

Report Scope

The Live Attenuated Varicella Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Live Attenuated Varicella Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Live Attenuated Varicella Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Live Attenuated Varicella Vaccine Market Report

Report Metric	Details
Report Name	Live Attenuated Varicella Vaccine Market
Accounted market size in 2023	US$ 4174 million
Forecasted market size in 2030	US$ 5693.2 million
CAGR	4.6%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Monovalent Vaccine Combination Vaccine
Segment by Application	Kids Injection Adults Injection
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	MerckVaccines, GSK, BCHT, Changsheng Bioscience, Keygen Biological, GC Biopharma, Biken, ChangChun High & New Technology, Sinovac
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Live Attenuated Varicella Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Live Attenuated Varicella Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Live Attenuated Varicella Vaccine Market growing?

Ans: The Live Attenuated Varicella Vaccine Market witnessing a CAGR of 4.6% during the forecast period 2024-2030.

What is the Live Attenuated Varicella Vaccine Market size in 2030?

Ans: The Live Attenuated Varicella Vaccine Market size in 2030 will be US$ 5693.2 million.

Who are the main players in the Live Attenuated Varicella Vaccine Market report?

Ans: The main players in the Live Attenuated Varicella Vaccine Market are MerckVaccines, GSK, BCHT, Changsheng Bioscience, Keygen Biological, GC Biopharma, Biken, ChangChun High & New Technology, Sinovac

What are the Application segmentation covered in the Live Attenuated Varicella Vaccine Market report?

Ans: The Applications covered in the Live Attenuated Varicella Vaccine Market report are Kids Injection, Adults Injection

What are the Type segmentation covered in the Live Attenuated Varicella Vaccine Market report?

Ans: The Types covered in the Live Attenuated Varicella Vaccine Market report are Monovalent Vaccine, Combination Vaccine

1 Live Attenuated Varicella Vaccine Market Overview

1.1 Product Overview and Scope of Live Attenuated Varicella Vaccine

1.2 Live Attenuated Varicella Vaccine Segment by Type

1.2.1 Global Live Attenuated Varicella Vaccine Market Value Comparison by Type (2024-2030)

1.2.2 Monovalent Vaccine

1.2.3 Combination Vaccine

1.3 Live Attenuated Varicella Vaccine Segment by Application

1.3.1 Global Live Attenuated Varicella Vaccine Market Value by Application: (2024-2030)

1.3.2 Kids Injection

1.3.3 Adults Injection

1.4 Global Live Attenuated Varicella Vaccine Market Size Estimates and Forecasts

1.4.1 Global Live Attenuated Varicella Vaccine Revenue 2019-2030

1.4.2 Global Live Attenuated Varicella Vaccine Sales 2019-2030

1.4.3 Global Live Attenuated Varicella Vaccine Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Live Attenuated Varicella Vaccine Market Competition by Manufacturers

2.1 Global Live Attenuated Varicella Vaccine Sales Market Share by Manufacturers (2019-2024)

2.2 Global Live Attenuated Varicella Vaccine Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Live Attenuated Varicella Vaccine Average Price by Manufacturers (2019-2024)

2.4 Global Live Attenuated Varicella Vaccine Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Live Attenuated Varicella Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Live Attenuated Varicella Vaccine, Product Type & Application

2.7 Live Attenuated Varicella Vaccine Market Competitive Situation and Trends

2.7.1 Live Attenuated Varicella Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Live Attenuated Varicella Vaccine Players Market Share by Revenue

2.7.3 Global Live Attenuated Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Live Attenuated Varicella Vaccine Retrospective Market Scenario by Region

3.1 Global Live Attenuated Varicella Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Live Attenuated Varicella Vaccine Global Live Attenuated Varicella Vaccine Sales by Region: 2019-2030

3.2.1 Global Live Attenuated Varicella Vaccine Sales by Region: 2019-2024

3.2.2 Global Live Attenuated Varicella Vaccine Sales by Region: 2025-2030

3.3 Global Live Attenuated Varicella Vaccine Global Live Attenuated Varicella Vaccine Revenue by Region: 2019-2030

3.3.1 Global Live Attenuated Varicella Vaccine Revenue by Region: 2019-2024

3.3.2 Global Live Attenuated Varicella Vaccine Revenue by Region: 2025-2030

3.4 North America Live Attenuated Varicella Vaccine Market Facts & Figures by Country

3.4.1 North America Live Attenuated Varicella Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Live Attenuated Varicella Vaccine Sales by Country (2019-2030)

3.4.3 North America Live Attenuated Varicella Vaccine Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Live Attenuated Varicella Vaccine Market Facts & Figures by Country

3.5.1 Europe Live Attenuated Varicella Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Live Attenuated Varicella Vaccine Sales by Country (2019-2030)

3.5.3 Europe Live Attenuated Varicella Vaccine Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Live Attenuated Varicella Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Live Attenuated Varicella Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Live Attenuated Varicella Vaccine Sales by Country (2019-2030)

3.6.3 Asia Pacific Live Attenuated Varicella Vaccine Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Live Attenuated Varicella Vaccine Market Facts & Figures by Country

3.7.1 Latin America Live Attenuated Varicella Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Live Attenuated Varicella Vaccine Sales by Country (2019-2030)

3.7.3 Latin America Live Attenuated Varicella Vaccine Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Live Attenuated Varicella Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Live Attenuated Varicella Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Live Attenuated Varicella Vaccine Sales by Country (2019-2030)

3.8.3 Middle East and Africa Live Attenuated Varicella Vaccine Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Live Attenuated Varicella Vaccine Sales by Type (2019-2030)

4.1.1 Global Live Attenuated Varicella Vaccine Sales by Type (2019-2024)

4.1.2 Global Live Attenuated Varicella Vaccine Sales by Type (2025-2030)

4.1.3 Global Live Attenuated Varicella Vaccine Sales Market Share by Type (2019-2030)

4.2 Global Live Attenuated Varicella Vaccine Revenue by Type (2019-2030)

4.2.1 Global Live Attenuated Varicella Vaccine Revenue by Type (2019-2024)

4.2.2 Global Live Attenuated Varicella Vaccine Revenue by Type (2025-2030)

4.2.3 Global Live Attenuated Varicella Vaccine Revenue Market Share by Type (2019-2030)

4.3 Global Live Attenuated Varicella Vaccine Price by Type (2019-2030)

5 Segment by Application

5.1 Global Live Attenuated Varicella Vaccine Sales by Application (2019-2030)

5.1.1 Global Live Attenuated Varicella Vaccine Sales by Application (2019-2024)

5.1.2 Global Live Attenuated Varicella Vaccine Sales by Application (2025-2030)

5.1.3 Global Live Attenuated Varicella Vaccine Sales Market Share by Application (2019-2030)

5.2 Global Live Attenuated Varicella Vaccine Revenue by Application (2019-2030)

5.2.1 Global Live Attenuated Varicella Vaccine Revenue by Application (2019-2024)

5.2.2 Global Live Attenuated Varicella Vaccine Revenue by Application (2025-2030)

5.2.3 Global Live Attenuated Varicella Vaccine Revenue Market Share by Application (2019-2030)

5.3 Global Live Attenuated Varicella Vaccine Price by Application (2019-2030)

6 Key Companies Profiled

6.1 MerckVaccines

6.1.1 MerckVaccines Corporation Information

6.1.2 MerckVaccines Description and Business Overview

6.1.3 MerckVaccines Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.1.4 MerckVaccines Live Attenuated Varicella Vaccine Product Portfolio

6.1.5 MerckVaccines Recent Developments/Updates

6.2 GSK

6.2.1 GSK Corporation Information

6.2.2 GSK Description and Business Overview

6.2.3 GSK Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.2.4 GSK Live Attenuated Varicella Vaccine Product Portfolio

6.2.5 GSK Recent Developments/Updates

6.3 BCHT

6.3.1 BCHT Corporation Information

6.3.2 BCHT Description and Business Overview

6.3.3 BCHT Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 BCHT Live Attenuated Varicella Vaccine Product Portfolio

6.3.5 BCHT Recent Developments/Updates

6.4 Changsheng Bioscience

6.4.1 Changsheng Bioscience Corporation Information

6.4.2 Changsheng Bioscience Description and Business Overview

6.4.3 Changsheng Bioscience Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Changsheng Bioscience Live Attenuated Varicella Vaccine Product Portfolio

6.4.5 Changsheng Bioscience Recent Developments/Updates

6.5 Keygen Biological

6.5.1 Keygen Biological Corporation Information

6.5.2 Keygen Biological Description and Business Overview

6.5.3 Keygen Biological Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Keygen Biological Live Attenuated Varicella Vaccine Product Portfolio

6.5.5 Keygen Biological Recent Developments/Updates

6.6 GC Biopharma

6.6.1 GC Biopharma Corporation Information

6.6.2 GC Biopharma Description and Business Overview

6.6.3 GC Biopharma Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 GC Biopharma Live Attenuated Varicella Vaccine Product Portfolio

6.6.5 GC Biopharma Recent Developments/Updates

6.7 Biken

6.6.1 Biken Corporation Information

6.6.2 Biken Description and Business Overview

6.6.3 Biken Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Biken Live Attenuated Varicella Vaccine Product Portfolio

6.7.5 Biken Recent Developments/Updates

6.8 ChangChun High & New Technology

6.8.1 ChangChun High & New Technology Corporation Information

6.8.2 ChangChun High & New Technology Description and Business Overview

6.8.3 ChangChun High & New Technology Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.8.4 ChangChun High & New Technology Live Attenuated Varicella Vaccine Product Portfolio

6.8.5 ChangChun High & New Technology Recent Developments/Updates

6.9 Sinovac

6.9.1 Sinovac Corporation Information

6.9.2 Sinovac Description and Business Overview

6.9.3 Sinovac Live Attenuated Varicella Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sinovac Live Attenuated Varicella Vaccine Product Portfolio

6.9.5 Sinovac Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Live Attenuated Varicella Vaccine Industry Chain Analysis

7.2 Live Attenuated Varicella Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Live Attenuated Varicella Vaccine Production Mode & Process

7.4 Live Attenuated Varicella Vaccine Sales and Marketing

7.4.1 Live Attenuated Varicella Vaccine Sales Channels

7.4.2 Live Attenuated Varicella Vaccine Distributors

7.5 Live Attenuated Varicella Vaccine Customers

8 Live Attenuated Varicella Vaccine Market Dynamics

8.1 Live Attenuated Varicella Vaccine Industry Trends

8.2 Live Attenuated Varicella Vaccine Market Drivers

8.3 Live Attenuated Varicella Vaccine Market Challenges

8.4 Live Attenuated Varicella Vaccine Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

ChangChun High & New Technology

MerckVaccines

Changsheng Bioscience

Keygen Biological

List of Tables

Table 1. Global Live Attenuated Varicella Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Live Attenuated Varicella Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Live Attenuated Varicella Vaccine Market Competitive Situation by Manufacturers in 2023

Table 4. Global Live Attenuated Varicella Vaccine Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Live Attenuated Varicella Vaccine Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Live Attenuated Varicella Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Live Attenuated Varicella Vaccine Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Live Attenuated Varicella Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Live Attenuated Varicella Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Live Attenuated Varicella Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Live Attenuated Varicella Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Live Attenuated Varicella Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Live Attenuated Varicella Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Varicella Vaccine as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Live Attenuated Varicella Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Live Attenuated Varicella Vaccine Sales by Region (2019-2024) & (K Units)

Table 18. Global Live Attenuated Varicella Vaccine Sales Market Share by Region (2019-2024)

Table 19. Global Live Attenuated Varicella Vaccine Sales by Region (2025-2030) & (K Units)

Table 20. Global Live Attenuated Varicella Vaccine Sales Market Share by Region (2025-2030)

Table 21. Global Live Attenuated Varicella Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Live Attenuated Varicella Vaccine Revenue Market Share by Region (2019-2024)

Table 23. Global Live Attenuated Varicella Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Live Attenuated Varicella Vaccine Revenue Market Share by Region (2025-2030)

Table 25. North America Live Attenuated Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Live Attenuated Varicella Vaccine Sales by Country (2019-2024) & (K Units)

Table 27. North America Live Attenuated Varicella Vaccine Sales by Country (2025-2030) & (K Units)

Table 28. North America Live Attenuated Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Live Attenuated Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Live Attenuated Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Live Attenuated Varicella Vaccine Sales by Country (2019-2024) & (K Units)

Table 32. Europe Live Attenuated Varicella Vaccine Sales by Country (2025-2030) & (K Units)

Table 33. Europe Live Attenuated Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Live Attenuated Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Live Attenuated Varicella Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Live Attenuated Varicella Vaccine Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Live Attenuated Varicella Vaccine Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Live Attenuated Varicella Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Live Attenuated Varicella Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Live Attenuated Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Live Attenuated Varicella Vaccine Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Live Attenuated Varicella Vaccine Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Live Attenuated Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Live Attenuated Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Live Attenuated Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Live Attenuated Varicella Vaccine Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Live Attenuated Varicella Vaccine Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Live Attenuated Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Live Attenuated Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Live Attenuated Varicella Vaccine Sales (K Units) by Type (2019-2024)

Table 51. Global Live Attenuated Varicella Vaccine Sales (K Units) by Type (2025-2030)

Table 52. Global Live Attenuated Varicella Vaccine Sales Market Share by Type (2019-2024)

Table 53. Global Live Attenuated Varicella Vaccine Sales Market Share by Type (2025-2030)

Table 54. Global Live Attenuated Varicella Vaccine Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Live Attenuated Varicella Vaccine Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Live Attenuated Varicella Vaccine Revenue Market Share by Type (2019-2024)

Table 57. Global Live Attenuated Varicella Vaccine Revenue Market Share by Type (2025-2030)

Table 58. Global Live Attenuated Varicella Vaccine Price (US$/Unit) by Type (2019-2024)

Table 59. Global Live Attenuated Varicella Vaccine Price (US$/Unit) by Type (2025-2030)

Table 60. Global Live Attenuated Varicella Vaccine Sales (K Units) by Application (2019-2024)

Table 61. Global Live Attenuated Varicella Vaccine Sales (K Units) by Application (2025-2030)

Table 62. Global Live Attenuated Varicella Vaccine Sales Market Share by Application (2019-2024)

Table 63. Global Live Attenuated Varicella Vaccine Sales Market Share by Application (2025-2030)

Table 64. Global Live Attenuated Varicella Vaccine Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Live Attenuated Varicella Vaccine Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Live Attenuated Varicella Vaccine Revenue Market Share by Application (2019-2024)

Table 67. Global Live Attenuated Varicella Vaccine Revenue Market Share by Application (2025-2030)

Table 68. Global Live Attenuated Varicella Vaccine Price (US$/Unit) by Application (2019-2024)

Table 69. Global Live Attenuated Varicella Vaccine Price (US$/Unit) by Application (2025-2030)

Table 70. MerckVaccines Corporation Information

Table 71. MerckVaccines Description and Business Overview

Table 72. MerckVaccines Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. MerckVaccines Live Attenuated Varicella Vaccine Product

Table 74. MerckVaccines Recent Developments/Updates

Table 75. GSK Corporation Information

Table 76. GSK Description and Business Overview

Table 77. GSK Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. GSK Live Attenuated Varicella Vaccine Product

Table 79. GSK Recent Developments/Updates

Table 80. BCHT Corporation Information

Table 81. BCHT Description and Business Overview

Table 82. BCHT Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. BCHT Live Attenuated Varicella Vaccine Product

Table 84. BCHT Recent Developments/Updates

Table 85. Changsheng Bioscience Corporation Information

Table 86. Changsheng Bioscience Description and Business Overview

Table 87. Changsheng Bioscience Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Changsheng Bioscience Live Attenuated Varicella Vaccine Product

Table 89. Changsheng Bioscience Recent Developments/Updates

Table 90. Keygen Biological Corporation Information

Table 91. Keygen Biological Description and Business Overview

Table 92. Keygen Biological Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Keygen Biological Live Attenuated Varicella Vaccine Product

Table 94. Keygen Biological Recent Developments/Updates

Table 95. GC Biopharma Corporation Information

Table 96. GC Biopharma Description and Business Overview

Table 97. GC Biopharma Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. GC Biopharma Live Attenuated Varicella Vaccine Product

Table 99. GC Biopharma Recent Developments/Updates

Table 100. Biken Corporation Information

Table 101. Biken Description and Business Overview

Table 102. Biken Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Biken Live Attenuated Varicella Vaccine Product

Table 104. Biken Recent Developments/Updates

Table 105. ChangChun High & New Technology Corporation Information

Table 106. ChangChun High & New Technology Description and Business Overview

Table 107. ChangChun High & New Technology Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. ChangChun High & New Technology Live Attenuated Varicella Vaccine Product

Table 109. ChangChun High & New Technology Recent Developments/Updates

Table 110. Sinovac Corporation Information

Table 111. Sinovac Description and Business Overview

Table 112. Sinovac Live Attenuated Varicella Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Sinovac Live Attenuated Varicella Vaccine Product

Table 114. Sinovac Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Live Attenuated Varicella Vaccine Distributors List

Table 118. Live Attenuated Varicella Vaccine Customers List

Table 119. Live Attenuated Varicella Vaccine Market Trends

Table 120. Live Attenuated Varicella Vaccine Market Drivers

Table 121. Live Attenuated Varicella Vaccine Market Challenges

Table 122. Live Attenuated Varicella Vaccine Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Live Attenuated Varicella Vaccine

Figure 2. Global Live Attenuated Varicella Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Live Attenuated Varicella Vaccine Market Share by Type in 2023 & 2030

Figure 4. Monovalent Vaccine Product Picture

Figure 5. Combination Vaccine Product Picture

Figure 6. Global Live Attenuated Varicella Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Live Attenuated Varicella Vaccine Market Share by Application in 2023 & 2030

Figure 8. Kids Injection

Figure 9. Adults Injection

Figure 10. Global Live Attenuated Varicella Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Live Attenuated Varicella Vaccine Market Size (2019-2030) & (US$ Million)

Figure 12. Global Live Attenuated Varicella Vaccine Sales (2019-2030) & (K Units)

Figure 13. Global Live Attenuated Varicella Vaccine Average Price (US$/Unit) & (2019-2030)

Figure 14. Live Attenuated Varicella Vaccine Report Years Considered

Figure 15. Live Attenuated Varicella Vaccine Sales Share by Manufacturers in 2023

Figure 16. Global Live Attenuated Varicella Vaccine Revenue Share by Manufacturers in 2023

Figure 17. The Global 5 and 10 Largest Live Attenuated Varicella Vaccine Players: Market Share by Revenue in 2023

Figure 18. Live Attenuated Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 19. Global Live Attenuated Varicella Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 20. North America Live Attenuated Varicella Vaccine Sales Market Share by Country (2019-2030)

Figure 21. North America Live Attenuated Varicella Vaccine Revenue Market Share by Country (2019-2030)

Figure 22. United States Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 23. Canada Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Europe Live Attenuated Varicella Vaccine Sales Market Share by Country (2019-2030)

Figure 25. Europe Live Attenuated Varicella Vaccine Revenue Market Share by Country (2019-2030)

Figure 26. Germany Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. France Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. U.K. Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Italy Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Russia Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Live Attenuated Varicella Vaccine Sales Market Share by Region (2019-2030)

Figure 32. Asia Pacific Live Attenuated Varicella Vaccine Revenue Market Share by Region (2019-2030)

Figure 33. China Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Japan Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. South Korea Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. India Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Australia Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. China Taiwan Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Indonesia Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Thailand Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Malaysia Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Live Attenuated Varicella Vaccine Sales Market Share by Country (2019-2030)

Figure 43. Latin America Live Attenuated Varicella Vaccine Revenue Market Share by Country (2019-2030)

Figure 44. Mexico Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Live Attenuated Varicella Vaccine Sales Market Share by Country (2019-2030)

Figure 48. Middle East & Africa Live Attenuated Varicella Vaccine Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Live Attenuated Varicella Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Live Attenuated Varicella Vaccine by Type (2019-2030)

Figure 53. Global Revenue Market Share of Live Attenuated Varicella Vaccine by Type (2019-2030)

Figure 54. Global Live Attenuated Varicella Vaccine Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Live Attenuated Varicella Vaccine by Application (2019-2030)

Figure 56. Global Revenue Market Share of Live Attenuated Varicella Vaccine by Application (2019-2030)

Figure 57. Global Live Attenuated Varicella Vaccine Price (US$/Unit) by Application (2019-2030)

Figure 58. Live Attenuated Varicella Vaccine Value Chain

Figure 59. Live Attenuated Varicella Vaccine Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Distributors Profiles

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions